However, as the inflammation in CAPS patients is also driven by the mutations in NLRP3, novel molecules inhibiting NLRP3 inflammasome, such as tranilast and inzomelid, are currently also evaluated in phase I and II clinical trials (23, 25). The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.